Yeung DT, Shanmuganathan N, Reynolds J, et al; Australasian Leukaemia and Lymphoma Group. Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study. <i>Blood.</i> 2024;144(19):1993-2001.

In the visual abstract, in the first bullet point under "Outcomes," "MMR at 12 months was 79%, and MR4.5 at 24 months was 53%" should read "MMR by 12 months was 79%, and MR4.5 by 24 months was 53%."In the graph, in the text label for the MR4.5 curve, the MR4.5 by 24 months should be 52.9%,not 64.9%.The corrected visual abstract is shown below.